Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients

被引：0
作者：
J. Víšek
M. Bláha
V. Bláha
M. Lášticová
M. Lánska
C. Andrýs
J. Duintjer Tebbens
Ivone Cristina Igreja e Sá
K. Tripská
M. Vicen
I. Najmanová
P. Nachtigal
机构：
[1] University Hospital Hradec Králové and Charles University,Metabolism and Gerontology, 3rd Department of Internal Medicine, Faculty of Medicine in Hradec Králové
[2] University Hospital Hradec Králové and Charles University,4th Department of Medicine
[3] University Hospital Hradec Králové and Charles University, Hematology, Faculty of Medicine in Hradec Králové
[4] Charles University,Department of Immunology and Allergology, Faculty of Medicine in Hradec Králové
[5] Charles University,Department of Biophysics and Physical Chemistry, Faculty of Pharmacy in Hradec Králové
来源：
Orphanet Journal of Rare Diseases | / 16卷
关键词：
Lipoprotein apheresis; Familial hypercholesterolemia; Lipids; Inflammation; Soluble endoglin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 141 条
  • [21] Blaha M(2011)Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis Pharmacol Res 20 127-526
  • [22] Lanska M(2019)2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk Atherosclerosis 24 1841-71
  • [23] Stefanutti C(2019)Mipomersen and its use in familial hypercholesterolemia Expert Opin Pharmacother 152 519-401
  • [24] Zenti MG(2017)Is lomitapide a life-saving drug in homozygous familial hypercholesterolemia Eur J Prev Cardiol 277 66-843
  • [25] Blaha V(2000)The rebound of lipoproteins after LDL-apheresis Kinetics and estimation of mean lipoprotein levels Atherosclerosis 2012 976578-2313
  • [26] Blaha M(2018)Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort Atherosclerosis 7 397-32
  • [27] Solichova D(2012)Changes in lipids and lipoproteins after selective LDL apheresis (7-year experience) Cholesterol 46 833-418
  • [28] Chepelenko GV(2003)Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia Therapeutic Apher Dial 52 2304-1426
  • [29] Ridker PM(2005)Ten-year follow-up of familial hypercholesterolemia patients after intensive cholesterol-lowering therapy Int Heart J 14 29-200
  • [30] Silvertown JD(2011)LDL-apheresis depletes apoE-HDL and pre-beta1-HDL in familial hypercholesterolemia: relevance to atheroprotection J Lipid Res 73 411-223
12345678910